about
Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton InvolvementThe pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomasGamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results.The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging.Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.Dopamine receptor agonists for treating prolactinomas.Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomasNerve growth factor suppresses the transforming phenotype of human prolactinomasSomatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumorsPharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.Resistant prolactinomas.The pituitary tumour epigenome: aberrations and prospects for targeted therapy.Current treatment options for hyperprolactinemia.Management of medically refractory prolactinoma.Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases.Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment.CV 205-502 treatment of macroprolactinomas.[Dopamine-agonist resistant prolactinomas: diagnosis and management].Growth factors in the pathogenesis of prolactin-secreting tumors.Cabergoline.Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.Treatment of prolactinomas.
P2860
Q26770701-AE673EA0-56E4-492E-B3EC-D1C54F565448Q26772167-31F3654E-B8E4-4031-9935-7FC2BEDE87D6Q30299965-A4C4A93E-EBFB-4D8B-936C-697A8DC7C34BQ33912655-FE7E1607-FA8E-4AC3-ADB0-E513126EB844Q34107624-E49DB5BB-1361-41C7-BAF3-68825478FC47Q34611189-96DBF65A-F4BA-4A37-A51C-C68B7E02CD03Q34660851-014A1B12-5FD8-40DF-A255-17DB5AF682E7Q35530288-81906CD6-8A99-4422-A8B2-29BD65BA8724Q36081822-30ECAF17-D113-405C-89B6-DFD7B0594B0DQ36501758-E4A5DABA-F563-4729-8511-B0CA7C330425Q37374477-B29B2FC2-4735-4498-B9D3-CD2F381E563FQ37636030-497E932E-0F2C-4E60-AA5E-0DFE07BE0571Q37853323-74E99E68-CB58-4732-B7F5-28EDF4BA5928Q38004744-0294494C-5C91-4584-9D71-46D674FB8085Q38112205-CF4298C4-255F-4DEF-A9C5-2A28E008171AQ38154516-1FDCA108-B6EB-4C47-91CE-F10FCD97E276Q39184902-A271686A-DEFC-4D93-890E-11F6E4CBB32DQ39198334-785A8A5D-ED1D-42F1-8022-041494E2033CQ42448698-6B590464-5444-41CF-A7D6-F7F618CF914CQ42474545-6B8F612F-F0D9-4060-9272-206B643D2527Q42488870-06BE1A8A-2B75-4A95-B944-36C4E2D00BADQ43583603-06AFEBCF-AE50-43F7-B651-693E51FA55A1Q43779440-20CA0188-168E-4662-8DB3-E50BCB535CCFQ45178194-814EED22-A357-47AA-8297-D53261D381A2Q46917426-7F986B0D-C75B-4B5F-BA64-B5AB006D3F6EQ47706708-8139F0AE-C134-4241-91C3-56AEDC1CF8B3Q48952149-B2427490-DC5D-4A12-A624-3F98C3129E88Q49717139-C5CDA700-43E3-494B-B2AA-79075FD7CB69Q54117059-9E0F2503-55DF-4CF4-AE0C-C359B5206C71
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Resistance to bromocriptine in prolactinomas.
@en
Resistance to bromocriptine in prolactinomas.
@nl
type
label
Resistance to bromocriptine in prolactinomas.
@en
Resistance to bromocriptine in prolactinomas.
@nl
prefLabel
Resistance to bromocriptine in prolactinomas.
@en
Resistance to bromocriptine in prolactinomas.
@nl
P2093
P356
P1476
Resistance to bromocriptine in prolactinomas.
@en
P2093
Bertrand P
Enjalbert A
Jedynak CP
Pellegrini I
Rasolonjanahary R
P304
P356
10.1210/JCEM-69-3-500
P407
P577
1989-09-01T00:00:00Z